Semaglutide for belly fat and liver health in kidney disease
Part of Digestive system, Heart & circulation, Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study looks at whether semaglutide (a diabetes medication) affects belly fat and the liver in people who have both type 2 diabetes and chronic kidney disease. It aims to understand if the drug can improve these health markers even in patients with reduced kidney function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have had type 2 diabetes for more than a year and a half.
- You must have some level of chronic kidney disease (CKD), but not the most severe stage or needing dialysis.
- You cannot be pregnant, breastfeeding, or planning to become pregnant.
- You must be willing to sign a consent form and agree to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether the oral medication semaglutide can help treat chronic kidney disease in people who have both type 2 diabetes and a fatty liver related to metabolism. It aims to see if the drug can improve kidney function and liver health.
This trial tests whether semaglutide (a diabetes drug) can help protect kidney function in people with type 2 diabetes who already have mild to moderate kidney damage. You will take semaglutide or a placebo and have regular kidney function tests.
This Phase 2 study tests semaglutide (a diabetes and weight-related medicine) to see if it can slow or improve diabetic kidney disease in people with type 1 diabetes. You may be able to join if you have type 1 diabetes for at least 5 years and ongoing signs of kidney damage measured in urine tests.
This study looks at how semaglutide (a medication for type 2 diabetes or weight management) affects your heart, kidneys, and overall metabolic health over time. It uses medical records from LMC endocrinology clinics to track real-world outcomes.
This trial tests whether semaglutide (a medicine that helps control blood sugar and weight) can improve outcomes for people with type 1 diabetes who have a higher body weight. It may help if you have had type 1 diabetes for at least 3 years and have a BMI of 30 or more, or 27 or more with a related health problem.
This study tests a new medicine called NNC0487-0111 to see how well it helps people with excess body weight and type 2 diabetes lose weight, compared to another medicine called semaglutide. It may be an option if you have type 2 diabetes and are looking to manage your weight.
Hear when a new Obesity & Overweight trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.